AbbVie Inc. (0QCV.L)
| Previous Close | 146.95 |
| Open | 147.24 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 150.54 - 154.06 |
| 52 Week Range | 131.22 - 167.80 |
| Volume | |
| Avg. Volume | 108,198 |
| Market Cap | 219.147B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 0.21 |
| EPS (TTM) | 6.97 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireRobert A. Michael Assumes Role as AbbVie Chief Executive Officer
AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company's inception in 2013. Mr. Gonzalez has become executive chairman of the board of directors.
- Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
Simply Wall St.AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past year...
